Free Trial
→ My next big call (under $1) (From Crypto 101 Media) (Ad)tc pixel Free NMTR Stock Alerts

9 Meters Biopharma (NMTR) Competitors

9 Meters Biopharma logo
Compare

NMTR vs. TRAW, ADXN, RDHL, CVKD, and SXTP

Should you buy 9 Meters Biopharma stock or one of its competitors? 9 Meters Biopharma's main competitors and comparable companies include Traws Pharma (TRAW), Addex Therapeutics (ADXN), Redhill Biopharma (RDHL), Cadrenal Therapeutics (CVKD), and 60 Degrees Pharmaceuticals (SXTP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does 9 Meters Biopharma compare to Traws Pharma?

Traws Pharma (NASDAQ:TRAW) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

In the previous week, Traws Pharma had 4 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 4 mentions for Traws Pharma and 0 mentions for 9 Meters Biopharma. Traws Pharma's average media sentiment score of 0.52 beat 9 Meters Biopharma's score of 0.00 indicating that Traws Pharma is being referred to more favorably in the media.

Company Overall Sentiment
Traws Pharma Positive
9 Meters Biopharma Neutral

Traws Pharma currently has a consensus price target of $1.00, suggesting a potential upside of 251.12%. Given Traws Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Traws Pharma is more favorable than 9 Meters Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Traws Pharma
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

9 Meters Biopharma's return on equity of -584.97% beat Traws Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Traws PharmaN/A -23,868.92% -165.52%
9 Meters Biopharma N/A -584.97%-159.45%

Traws Pharma has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market.

Traws Pharma has higher revenue and earnings than 9 Meters Biopharma. Traws Pharma is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Traws Pharma$2.79M1.57$9.17M-$1.74N/A
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A

8.0% of Traws Pharma shares are owned by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are owned by institutional investors. 8.7% of Traws Pharma shares are owned by company insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Traws Pharma beats 9 Meters Biopharma on 9 of the 12 factors compared between the two stocks.

How does 9 Meters Biopharma compare to Addex Therapeutics?

Addex Therapeutics (NASDAQ:ADXN) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Given 9 Meters Biopharma's higher possible upside, analysts plainly believe 9 Meters Biopharma is more favorable than Addex Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Addex Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Addex Therapeutics has higher revenue and earnings than 9 Meters Biopharma. Addex Therapeutics is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Addex Therapeutics$210K30.98-$8.12M-$5.94N/A
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A

Addex Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market.

In the previous week, Addex Therapeutics had 6 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 6 mentions for Addex Therapeutics and 0 mentions for 9 Meters Biopharma. Addex Therapeutics' average media sentiment score of 0.52 beat 9 Meters Biopharma's score of 0.00 indicating that Addex Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Addex Therapeutics Positive
9 Meters Biopharma Neutral

16.1% of Addex Therapeutics shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 15.0% of Addex Therapeutics shares are held by insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Addex Therapeutics' return on equity of -174.44% beat 9 Meters Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Addex TherapeuticsN/A -174.44% -126.47%
9 Meters Biopharma N/A -584.97%-159.45%

Summary

Addex Therapeutics beats 9 Meters Biopharma on 9 of the 13 factors compared between the two stocks.

How does 9 Meters Biopharma compare to Redhill Biopharma?

Redhill Biopharma (NASDAQ:RDHL) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

In the previous week, Redhill Biopharma had 2 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 2 mentions for Redhill Biopharma and 0 mentions for 9 Meters Biopharma. Redhill Biopharma's average media sentiment score of 1.39 beat 9 Meters Biopharma's score of 0.00 indicating that Redhill Biopharma is being referred to more favorably in the media.

Company Overall Sentiment
Redhill Biopharma Positive
9 Meters Biopharma Neutral

7.2% of Redhill Biopharma shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 6.8% of Redhill Biopharma shares are held by company insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Given 9 Meters Biopharma's higher possible upside, analysts clearly believe 9 Meters Biopharma is more favorable than Redhill Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Redhill Biopharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Redhill Biopharma's return on equity of 0.00% beat 9 Meters Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Redhill BiopharmaN/A N/A N/A
9 Meters Biopharma N/A -584.97%-159.45%

Redhill Biopharma has a beta of 4.93, meaning that its share price is 393% more volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market.

Redhill Biopharma has higher revenue and earnings than 9 Meters Biopharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Redhill Biopharma$290K11.68-$430KN/AN/A
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A

Summary

Redhill Biopharma beats 9 Meters Biopharma on 9 of the 11 factors compared between the two stocks.

How does 9 Meters Biopharma compare to Cadrenal Therapeutics?

Cadrenal Therapeutics (NASDAQ:CVKD) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

7.9% of Cadrenal Therapeutics shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 14.6% of Cadrenal Therapeutics shares are held by insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cadrenal Therapeutics' return on equity of -406.41% beat 9 Meters Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Cadrenal TherapeuticsN/A -406.41% -273.80%
9 Meters Biopharma N/A -584.97%-159.45%

Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cadrenal TherapeuticsN/AN/A-$13.24M-$4.90N/A
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A

Cadrenal Therapeutics has a beta of 1.94, meaning that its share price is 94% more volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market.

Cadrenal Therapeutics presently has a consensus target price of $13.00, suggesting a potential upside of 760.93%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cadrenal Therapeutics is more favorable than 9 Meters Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cadrenal Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Cadrenal Therapeutics had 2 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 2 mentions for Cadrenal Therapeutics and 0 mentions for 9 Meters Biopharma. Cadrenal Therapeutics' average media sentiment score of 0.91 beat 9 Meters Biopharma's score of 0.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Cadrenal Therapeutics Positive
9 Meters Biopharma Neutral

Summary

Cadrenal Therapeutics beats 9 Meters Biopharma on 9 of the 13 factors compared between the two stocks.

How does 9 Meters Biopharma compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

9 Meters Biopharma has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -650.21%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat 9 Meters Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
60 Degrees Pharmaceuticals-650.21% N/A -136.81%
9 Meters Biopharma N/A -584.97%-159.45%

60 Degrees Pharmaceuticals has higher revenue and earnings than 9 Meters Biopharma. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.41M1.30-$7.36M-$4.82N/A
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A

In the previous week, 60 Degrees Pharmaceuticals had 3 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 3 mentions for 60 Degrees Pharmaceuticals and 0 mentions for 9 Meters Biopharma. 60 Degrees Pharmaceuticals' average media sentiment score of 0.21 beat 9 Meters Biopharma's score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
60 Degrees Pharmaceuticals Neutral
9 Meters Biopharma Neutral

60 Degrees Pharmaceuticals has a beta of 2.47, indicating that its share price is 147% more volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market.

8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are held by company insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

60 Degrees Pharmaceuticals currently has a consensus price target of $13.85, indicating a potential upside of 2,569.11%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than 9 Meters Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
60 Degrees Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
9 Meters Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

60 Degrees Pharmaceuticals beats 9 Meters Biopharma on 10 of the 14 factors compared between the two stocks.

Get 9 Meters Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NMTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NMTR vs. The Competition

Export
Metric9 Meters BiopharmaPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.04M$13.79B$7.91B$12.24B
Dividend YieldN/A2.56%2.46%4.51%
P/E Ratio0.0025.6934.3428.45
Price / SalesN/A7.728.906.00
Price / CashN/A15.7922.2322.80
Price / BookN/A5.244.503.83
Net Income-$43.77M$2.87B$3.51B$390.69M

9 Meters Biopharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NMTR
9 Meters Biopharma
N/AN/AN/AN/A$1.04MN/AN/A20
TRAW
Traws Pharma
2.2008 of 5 stars		$0.22
-18.1%		$1.00
+354.3%		-86.7%$4.13M$2.79MN/A7
ADXN
Addex Therapeutics
0.4472 of 5 stars		$2.90
-4.6%		N/A-39.9%$3.75M$210KN/A3
RDHL
Redhill Biopharma
1.1319 of 5 stars		$0.43
+0.9%		N/A-64.4%$3.75M$290KN/A210
CVKD
Cadrenal Therapeutics
2.7083 of 5 stars		$1.00
-5.7%		$13.00
+1,200.0%		-87.7%$3.57MN/AN/A5

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NMTR) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...
Behind the Markets | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...
Paradigm Press | Sponsoredtc pixel
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...
Weiss Ratings | Sponsoredtc pixel